LAVI and Azanta enter agreement to provide Nimoral™ and Zybrestat™ in Israel on Compassionate Use Basis

2012-07-02

Hellerup, July 2, 2012.Azanta A/S,a Danish specialty pharmaceutical company and Lavi, an Israeli pharmaceutical company, have entered an exclusive agreement for the supply of Nimoral and Zybrestat in Israel. Lavi plans to make Nimoral and Zybrestat available on compassionate use basis.

Nimoral is a radiosensitizer used to enhance the effect of radiotherapy in head and neck cancer patients. Zybrestat represents a novel class of small-molecule drug candidates called vascular disrupting agents, and is used primarely against anaplastic thyroid cancer.

Dr. Claus Møller, Chief Executive Officer of Azanta A/S, commented:"The agreement with Lavi underlines our commitment to making novel cancer treatments available to patients. We are pleased to sign the agreement with Lavi, whom we believe will be an excellent partner to Azanta. This agreement marks our first entrance in the Middle East, and reflects our strategy to build industry leadership by making innovative therapies available to patients in international markets."

Dani Shaham, Acting Chairman and CO-CEO for Lavi,commented: "We are delighted to make such unique products as Nimoral and Zybrestat available in Israel. We are pleased to make our distribution network and regulatory expertise available to help advance these promising therapeutic options, and we look forward to a productive collaboration."

Under the terms of the agreement, Azanta will provide Nimoral and Zybrestat to Lavi at agreed-upon transfer prices. Lavi will serve as Azanta's exclusive distributor for the products in Israel for this purpose.

Nimoral and Zybrestat are already being made available under compassionate use programs for patients in the Nordic region and in Canada. Azanta has the global rights to Nimoral and has established a five-year partnership agreement with OXiGENE, Inc. that provides access to Zybrestat for the treatment of patients in Europe and Canada with anaplastic thyroid cancer (ATC) on a compassionate use basis. Pivotal confirmatory studies are either being planned or are ongoing for these products.

Azanta A/Sis a privately owned specialty pharma company primarily operating within oncology, women´s health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products. Azanta A/S currently markets or makes available a string of specialty pharma products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development projects for commercialization within the near future.

For further information, please visit www.azanta.com.

LAVI Ltd is a leading international company focused on the fields of novel medical devices, diagnostics, high quality niche pharmaceuticals, industrial products and pre-clinical imaging systems. Lavi, established in 1982, led by an experienced and educated management is poised to cope with the market trends and demands and therefore is able to offer unique  medical solutions to the Israeli medical and research fields. Lavi, as a leading group involved in the health industry, provides deep understanding of the global healthcare market and trends.

For further information, please visit www.laviltd.com.

 

 

Contact Azanta

Claus Møller

Tel:  + 45 - 70 25 95 45

Fax: + 45 - 70 25 95 46

Email: info@azanta.com

 

 

Contact Lavi

Dani Shaham

Tel.: +972 - 9 - 765-6701

Fax: +972 - 9 - 765-6697

Email: info@lavitld.com

Azanta A/S, Gearhalsvej 1, DK-2500 Valby, Denmark, Phone +45 7025 9545, Fax: +45 7025 9546, Mail: info@azanta.com

DisclaimerAll rights reserved ©